Speakers
Nicolas Ferry
Chief Development Officer
Horama
Day Two
Thursday 13th December 2018
4:30 pm | Q&A Panel Discussion
3:50 pm | Understanding the Pre-Clinical Regulators’ Expectations for Gene Therapy Trials
Peter Campochiaro
Director, Retinal Cell & Molecular Laboratory; Professor of Ophthalmology
Johns Hopkins University School of Medicine
Rei Nakamura
Clinical Country Lead
Biogen
Day Two
Thursday 13th December 2018
4:30 pm | Q&A Panel Discussion
Sanford Boye
Director of Vector Core, Powell Gene Therapy Center University of Florida
Chief Technology Officer Atsena Therapeutics
Shannon Boye
Founder & Chief Scientific Officer
Atsena Therapeutics
Day One
Thursday 13th December 2018
5:00 pm | Q&A Panel Discussion
4:20 pm | Gene Therapy for GUCY2D Leber Congenital Amaurosis (LCA1)
Abraham Scaria
Chief Scientific Offier
IVERIC Bio
Day One
Thursday 13th December 2018
12:00 pm | Q&A Panel Discussion
11:40 am | The Single AAV-minigene Approach for Delivery of Large Genes to the Retina • AAV vectors are efficacious for gene delivery to the retina
Aniz Girach
Chief Medical Officer
ProQR
Claire Gelfman
Chief Scientific Officer
Foundation Fighting Blindness
Day Two
Thursday 13th December 2018
4:30 pm | Q&A Panel Discussion
4:10 pm | Session Reserved for Foundation Fighting Blindness
Daniel Chung
Chief Medical Officer
SparingVision
Day One
Thursday 13th December 2018
3:00 pm | Q&A Panel Discussion
2:40 pm | Defining Novel Endpoints for IRDs
Day Two
Thursday 13th December 2018
2:00 pm | Q&A Panel Discussion
1:00 pm | Gene Agnostic Approaches Targeting Later Stage Diseases for Photoreceptor Function
Dominik Fischer
Principal Investigator & Consultant Ophthalmic Surgeon
Oxford Eye Hospital
Eric Kelsic
Chief Executive Officer
Dyno Therapeutics
Day Two
Thursday 13th December 2018
11:20 am | Q&A Panel Discussion
10:30 am | Machine Guided Capsid Engineering for Ocular Diseases
Francine Behar-Cohen
Founder & Chief Innovation Officer
Eyevensys
Day Two
Thursday 13th December 2018
11:20 am | Q&A Panel Discussion
10:50 am | Non-Viral Vectors for Lower Cost Manufacturing & Immune Mitigation
Gaelle Lefevre
Head of Project Management
HORAMA
Day One
Thursday 13th December 2018
3:00 pm | Q&A Panel Discussion
2:00 pm | Measuring Transduction Efficiency in Preclinical Ocular Models
Gil Carrasquinho
Vice President & Head of Cell Therapy
Santen
Day Two
Thursday 13th December 2018
2:00 pm | Q&A Panel Discussion
1:40 pm | The Potential of Intravitreal Human Retinal Progenitor Cells (hRPCs) in Inherited Retinal Disorders
Glenn Yiu
Associate Professor
University of California, Davis
Day Two
Thursday 13th December 2018
9:00 am | Q&A Panel Discussion
8:40 am | Host Immunity after Suprachoroidal AAV in Nonhuman Primates
Jacque Duncan
Professor, Clinical Ophthalmology
University of California San Fransisco
Day One
Thursday 13th December 2018
3:00 pm | Q&A Panel Discussion
2:20 pm | Outcome Measures for Clinical Trials In Inherited Retinal Degenerations
Jake Ternent
Patient
Luxterna
Day One
Thursday 13th December 2018
4:00 pm | A Patient’s Perspective: Jake’s Story & Q&A Session
José-Alain Sahel
Chairman & Professor, Ophthalmology
University of Pittsburgh
Day Two
Thursday 13th December 2018
9:00 am | Q&A Panel Discussion
8:20 am | Retinitis Pigmentosa to Dry AMD: A Clinical Update on Optogenetic Therapy
Magali Taiel
Chief Medical Officer
GenSight Biologics
Day Two
Thursday 13th December 2018
4:30 pm | Q&A Panel Discussion
3:30 pm | Lumevoq Gene Therapy in Leber Hereditary Optic Neuropathy (LHON): Regulatory Considerations: US & Europe Regulators
Nadia Waheed
Associate Professor in Ophthalmology Tufts University Medical School
Chief Medical Officer Gyroscope Therapeutics
Day One
Thursday 13th December 2018
9:20 am | Q&A Panel Discussion
8:10 am | Rare Vs Common Disorders: Structural & Functional Endpoints for Clinical Trials in AMD & Diabetic Retinopathy
Sheila Nirenberg
Professor & Founder
Bionic Sight
Day Two
Thursday 13th December 2018
2:00 pm | Q&A Panel Discussion
1:20 pm | First Four Patients in Bionic Sight’s Optogenetic Gene Therapy Trial Detect Light & Motion
Stavros Ntogiako
Head of Luxturna & Gene Therapy
Novartis
Day One
Thursday 13th December 2018
9:20 am | Q&A Panel Discussion
8:50 am | Approaching Commercialization Hurdles: Other Treatments Available, Pricing & Reimbursement
Stephen Poor
Director of External Opportunities & Translational Biomarkers
Novartis
Day Two
Thursday 13th December 2018
2:30 pm | Panel: Discussing Pharma Partnering & Collaboration: Challenges & Opportunities
Steve Pakola
Chief Medical Officer
REGENXBIO
Day One
Thursday 13th December 2018
5:00 pm | Q&A Panel Discussion
4:40 pm | Comparing Clinical Progress with Different Administration Routes
Stylianos Michalakis
Co-founder & Chief Scientific Advisor
ViGeneron
Day Two
Thursday 13th December 2018
11:20 am | Q&A Panel Discussion
11:10 am | Retinal Gene Therapy: Novel Vector Technologies
Sue Washer
Chief Executive Officer
AGTC
Day One
Thursday 13th December 2018
12:00 pm | Q&A Panel Discussion
11:00 am | Preclinical Challenges with Preclinical Models, Measuring Genetic Expression & Variability of Transfer
Thomas Ciulla
Vitreoretinal Medicine & Surgery, Chief Medical Officer & Chief Development Officer
Clearside Biomedical Inc.
Day One
Thursday 13th December 2018
9:20 am | Q&A Panel Discussion
8:30 am | Evaluating the Promise of Suprachoroidal Delivery for Retinal Expression
Virginia Haurigot
Head of Ocular Research
Spark Therapeutics
Day One
Thursday 13th December 2018
12:00 pm | Q&A Panel Discussion
11:20 am | Session Reserved
Ying Kai Chan
Visiting Scholar
Harvard University
Day Two
Thursday 13th December 2018
9:00 am | Q&A Panel Discussion
8:10 am | Landscape of Ocular Gene Therapy Immunogenicity & Vector Strategies to Overcome Inflammation
Udo Maier
Head of Research Beyond Borders Europe
Boehringer Ingelheim
Day Two
Thursday 13th December 2018
2:30 pm | Panel: Discussing Pharma Partnering & Collaboration: Challenges & Opportunities
